This test examines 98 genes across 24 hereditary cancers using its proprietary SMSEQ platform.
The CellMax-DNA Genetic Cancer Risk Test requires only a saliva sample.
CellMax Life's DNA test uses next generation sequencing to detect gene mutations known to increase lifetime cancer risk.
The test surveys for increased risk of 24 cancers including some of the most common cancers: breast, lip, lung, colorectal and stomach, along with prostate, bladder, thyroid, ovary and others.
As an example of the extensive breadth of the gene panel analyzed by CellMax Life, to assess breast cancer risk, the CellMax-DNA test covers BRCA1 and BRCA2 genes entirely, and also examines a number of other genes associated with breast cancer, including ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, PPM1D, PTEN, RAD51C, RAD51D, STK11, and TP53.
Genetic mutations associated with increased cancer risk are passed from parent to offspring. These inherited abnormal genes are in contrast to acquired mutations which occur after birth and over time, and include environmental factors and lifestyle choices such as smoking or sun exposure.
Individuals with certain inherited genetic mutations carry a higher lifetime risk for various cancers. Their risk of getting these cancers can be up to 20 times greater than individuals without these mutations.
Cancers impacted by these inherited gene mutations are typically referred to as hereditary cancers.
CellMax Life provides personalised multi-biomarker technology platforms for genetic cancer risk assessment, early detection and personalized treatment of cancer.
Clongen Laboratories to launch sister company Clongen Pharma LLC
Curasight's uTREAT clinical trial application approved in Europe
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Citius Oncology deploys AI platform to assist commercial team ahead of LYMPHIR launch
Innovent Biologics receives approval over squamous cell lung cancer study
Hamlet BioPharma completes Phase II study of Alpha1H in non-muscle invasive bladder cancer
Zelluna ASA announces Q2 2025 financial results and business update
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Agilent's MMR IHC Panel gains FDA approval as colorectal cancer companion diagnostic test
HUTCHMED completes enrollment in Phase III SANOVO trial of ORPATHYS and TAGRISSO in China
ANGLE partners with Myriad Genetics on circulating tumour cell DNA feasibility study
Immunovia to launch PancreaSure in US market in September with phased commercial rollout
Soligenix' dusquetide granted US FDA orphan drug designation to treat Behcet's Disease